SOPHiA GENETICS Reports First Quarter 2024 ResultsConsistent Operational Execution; Robust New Business Momentum; Guidance Reaffirmed
SOPHiA GENETICS to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceBOSTON and ROLLE, Switzerland, April 30, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced that Chief Financial Officer and Chief Operating Officer, Ross Muken, will present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City on Tuesday, May 14, 2024, at 3:35 p.m. EDT.
SOPHiA GENETICS to Announce Financial Results for First Quarter 2024 on May 7, 2024BOSTON and ROLLE, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal year 2024 before U.S. markets open on Tuesday, May 7, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.
SOPHiA GENETICS to Present at the Barclays 26th Annual Global Healthcare ConferenceBOSTON and ROLLE, Switzerland, March 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Chief Financial Officer and Chief Operating Officer, Ross Muken, will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13, 2024, at 2:35 p.m. EDT.
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 ResultsStrong momentum to continue in 2024 as SOPHiA GENETICS announces record revenue, 35 new customer additions in Q4, and 36% cash burn decline in FY 2023
SOPHiA GENETICS to Participate in Fireside Chat at the 44th Annual TD Cowen Health Care ConferenceBOSTON and ROLLE, Switzerland, Feb. 22, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Co-founder and Chief Executive Officer, Dr. Jurgi Camblong, and Chief Financial Officer and Chief Operating Officer, Ross Muken, will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Wednesday, March 6, 2024, at 10:30 a.m. EDT.
SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024BOSTON and ROLLE, Switzerland, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full-year 2023 before U.S. markets open on Tuesday, March 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.
SOPHiA GENETICS to Present at the J.P. Morgan 2024 Healthcare ConferenceBOSTON and ROLLE, Switzerland, Dec. 14, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (
NASDAQ: SOPH) today announced that Jurgi Camblong, PhD., Chief Executive Officer and Co-founder, is scheduled to present at the J.P. Morgan 2024 Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PST in San Francisco.
SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2023Record results on growth acceleration, significant improvement in operating loss and cash burn
SOPHiA GENETICS to Announce Financial Results for the Third Quarter of Fiscal 2023 on November 7, 2023BOSTON and GENEVA, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal 2023 before U.S. markets open on Tuesday, November 7, 2023. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EST / 2:00 p.m. (14:00) CEST.
SOPHiA GENETICS’ SOPHiA DDM™ HRD Solution is Tapped by Unipath Specialty Laboratory Limited
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Unipath Specialty Laboratory Limited, one of the leading diagnostic brands in India, is live on the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution. Using SOPHiA GENETICS’ technology, Unipath Specialty Laboratory Limited has launched HRD Gene Panel, its latest offering in the field of cancer genomics.
SOPHiA GENETICS Celebrates Swiss Biotech Award
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, was honored to accept the Swiss Biotech Success Stories Award from the Swiss Biotech Association. The Award recognizes SOPHiA GENETICS’ contributions in leading the way to democratizing data-driven medicine.
SOPHiA GENETICS to Announce Financial Results for the First Quarter of Fiscal 2023 on May 9, 2023BOSTON and GENEVA, Switzerland, April 25, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced it will release its financial results for the first quarter of fiscal 2023 before U.S. markets open on Tuesday, May 9, 2023. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CEST.
The University of Maryland Medical Center Chooses SOPHiA GENETICS Technology
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that the University of Maryland Medical Center (UMMC) is using SOPHiA GENETICS technology to enhance their capabilities around rare disease detection and treatment. UMMC has chosen SOPHiA Whole Exome Solution™ v2, a next-generation sequencing (NGS)-based application that provides a streamlined end-to-end workflow, to accelerate its rare and inherited disease research.
Krsnaa Diagnostics is Live on SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Krsnaa Diagnostics, India’s largest diagnostic services provider in radiology and pathology, is live on SOPHiA DDM™ technology. Krsnaa Diagnostics is using the SOPHiA DDM™ for Hereditary Cancers Solution to expand their current next-generation sequencing (NGS) offerings.
Tel Aviv Sourasky Medical Center Chooses SOPHiA DDMTM HRD Solution of SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Tel Aviv Sourasky Medical Center (Ichilov), the largest acute care facility in Israel, has chosen to use SOPHiA DDM™ to enhance its genetic testing capabilities. The facility, which serves a population of one million people, will use the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution to help advance its clinical oncology research.
Acutis Diagnostics Leverages SOPHiA GENETICS Technology to Create New Next Generation Sequencing Test
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Acutis Diagnostics, a specialized medical laboratory, will use SOPHiA DDM™ to develop a new genomic assay. This new next-generation sequencing (NGS) test will build on Acutis Diagnostics’ track record of approved lab-developed tests that support clinical trials, cancer research and treatment.
SOPHiA GENETICS and Agilent Partner on Comprehensive Solution for Cancer Analysis
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and the leader in data-driven medicine, is partnering with Agilent to offer a comprehensive solution for cancer analysis.
SOPHiA GENETICS Reports Fourth Quarter and Year End 2022 Financial Results
SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced financial results for its fourth quarter and full fiscal year ended December 31, 2022.
University of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and the leader in data-driven medicine, today announced the University of Arkansas for Medical Sciences (UAMS), based in Little Rock, AR, will use SOPHiA GENETICS’ platform to support their clinical oncology research. Beginning this year, UAMS will implement the SOPHiA DDM™ platform to gain deeper insights into hematologic malignancies.
SOPHiA GENETICS Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2023
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2023.
SOPHiA GENETICS and QIAGEN Forge Partnership to Combine Strengths in Next-generation Sequencing
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced a new partnership with QIAGEN N.V. (
NYSE: QGEN) that will pair QIAseq reagent technology with the SOPHiA DDM™ platform to enhance tumor analysis through next-generation sequencing (NGS).
